Nuveen LLC Invests $431,000 in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Nuveen LLC has acquired 37,321 shares of KalVista Pharmaceuticals, valued at approximately $431,000, marking a 0.08% ownership in the company according to its latest SEC filing.
• Several analysts have recently raised their price targets for KalVista Pharmaceuticals, with JMP Securities increasing theirs from $19 to $27, indicating strong market support for the stock.
• KalVista Pharmaceuticals reported a quarterly earnings per share of ($3.69), which missed the consensus estimate of ($0.83), reflecting ongoing financial challenges for the company.

Nuveen LLC purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 37,321 shares of the specialty pharmaceutical company's stock, valued at approximately $431,000. Nuveen LLC owned 0.08% of KalVista Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in KALV. Suvretta Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after buying an additional 701,007 shares during the period. Tang Capital Management LLC lifted its position in shares of KalVista Pharmaceuticals by 13.2% during the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock worth $41,451,000 after purchasing an additional 572,300 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock traded down $0.22 during trading hours on Wednesday, reaching $15.39. The company's stock had a trading volume of 858,951 shares, compared to its average volume of 782,052. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.33. The company's 50 day simple moving average is $14.04 and its 200 day simple moving average is $12.74. The stock has a market cap of $774.73 million, a P/E ratio of -4.17 and a beta of -0.10.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the business posted ($1.07) EPS. On average, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on KALV. Leerink Partners boosted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, July 7th. JMP Securities lifted their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. Finally, HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $26.29.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,294 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $15.84, for a total transaction of $115,536.96. Following the transaction, the chief executive officer owned 395,189 shares of the company's stock, valued at approximately $6,259,793.76. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,336 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the sale, the insider owned 122,505 shares of the company's stock, valued at $1,644,017.10. The trade was a 1.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,835 shares of company stock worth $892,350. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).